Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Christian Lienhardt

Christian Lienhardt Discusses the Newly Launched TB-PACTS Database

  Christian Lienhardt, from WHO, discusses the launch of TB-PACTS, the new data-sharing platform for TB clinical trials. This marks the beginning of an exciting new tool in the fight against TB. Announced on April 18th, TB-PACTS combines clinica...

Watch Video

View All Videos »

Dr. Iwao Ojima

TB R&D Update: Podcast Interview with Dr. Iwao Ojima

Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. In this interview, Dr. Ojima discusses the work his lab has been doing on tri-substituted benzimidazole compou...

Listing to Podcast

View All Podcasts »

exposed

UPDATE Exposed: Aeras’ Film Series on Tuberculosis

Release of Chapter 1 of EXPOSED occured the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals - an MDR...

Watch Video

View All Videos »

MSF video

Multidrug-Resistance Tuberculosis: No Promises

A video from Medecins Sans Frontieres entitled "Multidrug-Resistance Tuberculosis: No Promises" on the situation of children affected with MDR-TB. It highlights the dire plight of children being treated for MDR-TB in Tajikistan....

Watch Video

View All Videos »

previous next

Messages to our members

2015 WGND Annual Meeting Recap LIVE!

The 2015 WGND Annual Meeting took place in Cape Town, South Africa on Saturday, December 5th. Go to http://www.newtbdrugs.org/meetings/annual-meeting-2015.php to see agenda, presentations, and synopses.

View All Messages »

From the blog

Christian Lienhardt

Christian Lienhardt Discusses the Newly Launched TB-PACTS Database

  Christian Lienhardt, from WHO, discusses the launch of TB-PACTS, the new data-sharing platform for TB clinical trials. This marks the beginning of an exciting new tool in the fight against TB. Announced on April 18th, TB-PACTS combines clinical trial data from¬†Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases [...]

Posted 21 April 2016 | No Comments

A Slight Chemical Alteration Makes a TB Drug More Effective

Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here, researchers are reported to have found a chemical alteration that makes fluoroquinolones, an existing group of TB-fighting drugs, more effective against [...]

Posted 18 February 2016 | No Comments

Get involved

Site features

Global Discovery Programs

An online tool that invites developers to submit their discovery programs so we can provide a more complete snapshot of current global efforts.

View Pipeline

The Global TB Drugs Pipeline

An online tool that invites developers to submit their TB drug candidates so we can provide a more complete snapshot of current global efforts.

View Pipeline

TB Resources Database

A growing collection of resources to help access Tools, Knowledge, Facilities, and People in the TB drug development R&D community.

View TB Resources

Why We Need New TB Drugs

Today's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even lengthier, taking 18-24 months or longer.

Read More

About us

Our Mission

To accelerate the discovery and development of new drugs for the treatment of tuberculosis by bringing together the stakeholders in TB Drug Development, including the patients themselves.
Read More »

Global Members

The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.
Read More »

Total members: 269

WGND Members:

Tado Shimao

JATA Research Institute of Tuberculosis (RIT)

Barry Furr

Astrazeneca

Gerald Siuta

TB Alliance

Manjunatha Ujjini

Novartis Institute for Tropical Diseases

Nino Lomtadze

National Center for Tuberculosis and Lung Diseases

Christopher Cooper

Global Alliance for TB Drug Development (TB Alliance)

Daniel Zollinger

okklo life sciences

Omar Vandal

Bill and Melinda Gates Foundation

Gyanu Lamichhane

Johns Hopkins University

Jim Boyce

National Institute of Allergy and INfectious Diseases

View All Members »